Drug Price Transparency
Last week, I shared a few areas where we can advance health in America this year, even in a divided Congress. Number one on that list: reining in the skyrocketing costs of prescription drugs.
Drug spending is rising dramatically on top of historic growth. High drug prices create real challenges for hospitals and the patients they treat.
The 黑料正能量 Association (AHA), the Federation of 黑料正能量s (FAH), and the American Society of Health-System Pharmacists (ASHP) released a new report finding that continued rising drug prices, as well as shortages for many critical medications, are impacting patient care and鈥
The AHA today voiced support for a Centers for Medicare & Medicaid Services鈥 proposal to require drug pricing transparency in direct-to-consumer television advertisements and encouraged the agency to 鈥渞ein in skyrocketing drug prices鈥 for patients and the providers who serve them.
The AHA voiced support for a Centers for Medicare & Medicaid Services鈥 proposal to require drug pricing transparency in direct-to-consumer television advertisements and encouraged the agency to 鈥渞ein in skyrocketing drug prices鈥 for patients and the providers who serve them. 鈥淲e appreciate CMS鈥欌
The Centers for Medicare & Medicaid Services today issued a proposed rule aimed at increasing drug price transparency and reducing the price of prescription drugs and biological products to consumers by requiring drug manufacturers to include list prices in all direct-to-consumer television鈥
The House of Representatives yesterday passed two bills that would prohibit health plans from restricting a pharmacist鈥檚 ability to inform enrollees when a drug would cost less without using their insurance.
The Senate last night voted 98-2 to approve the Patient Right to Know Drug Prices Act (S. 2554), a bill that would prohibit private health plans from restricting a pharmacist鈥檚 ability to inform enrollees when a drug would cost less without using their insurance.
A coalition of health care providers, insurers, seniors and others is pushing back on some of the latest claims by the Pharmaceutical Research and Manufacturers of America that incorrectly blame hospitals for the rising price of drugs.